Proteomic typing of amyloid deposits in systemic amyloidoses

Amyloid

Volumn 18, Issue 4, 2011, Pages 177-182

  Lavatelli, Francesca ^a   Vrana, Julie A ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

Amyloid typing; Mass spectrometry; Proteomics

Indexed keywords

AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; APOLIPOPROTEIN E; GELSOLIN; IMMUNOGLOBULIN LIGHT CHAIN; SERUM AMYLOID A; SERUM AMYLOID P; TRYPSIN INHIBITOR;

AMINO ACID SUBSTITUTION; AMYLOIDOSIS; HUMAN; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; PROTEIN VARIANT; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL GEL ELECTROPHORESIS; WILD TYPE;

ADIPOSE TISSUE; AMYLOIDOGENIC PROTEINS; AMYLOIDOSIS; BIOPSY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MASS SPECTROMETRY; PROTEOMICS;

EID: 81255201265     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2011.630762     Document Type: Review

References (55)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-596. (Pubitemid 36951371)
2. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011;29:1924-1933.
3. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010;17:101-104.
4. Bergstrom J, Murphy C, Eulitz M, Weiss DT, Westermark GT, Solomon A, Westermark P. Codeposition of apolipoprotein A-IV and transthyretin in senile systemic (ATTR) amyloidosis. Biochem Biophys Res Commun 2001;285:903-908. (Pubitemid 32918021)
5. Elimova E, Kisilevsky R, Szarek WA, Ancsin JB. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J 2004;18:1749-1751. (Pubitemid 39561672)
6. Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 1994;91:5602-5606. (Pubitemid 24174376)
7. Kisilevsky R. The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000. Amyloid 2000;130:99-108.
8. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-1791. (Pubitemid 34586914)
9. Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006;107:3489-3491.
10. Picken MM. Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med 2010;134:545-551.
11. Picken MM, Herrera GA. The burden of "sticky" amyloid: typing challenges. Arch Pathol Lab Med 2007;131:850-851. (Pubitemid 46906375)
12. Solomon A, Murphy CL, Westermark P. Unreliability of immunohistochemistry for typing amyloid deposits. Arch Pathol Lab Med 2008;132:14; author reply 14-14; author reply 15.
13. Picken MM. New insights into systemic amyloidosis: the importance of diagnosis of specific type. Curr Opin Nephrol Hypertens 2007;16:196-203. (Pubitemid 46608527)
14. Davern S, Tang LX, Williams TK, Macy SD, Wall JS, Weiss DT, Solomon A. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol 2008;130:702-711.
15. Kebbel A, Rocken C. Immunohistochemical classification of amyloid in surgical pathology revisited. Am J Surg Pathol 2006;30:673-683. (Pubitemid 44264992)
16. Linke RP, Oos R, Wiegel NM, Nathrath WB. Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem 2006;108:197-208. (Pubitemid 44015876)
17. Rocken C, Schwotzer EB, Linke RP, Saeger W. The classification of amyloid deposits in clinicopathological practice. Histopathology 1996;29:325-335. (Pubitemid 26338436)
18. Lavatelli F, Valentini V, Palladini G, Verga L, Russo P, Foli A, Obici L, et al. Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. Amyloid 2011;18 Suppl 1:59-61.
19. Murphy CL, Wang S, Williams T, Weiss DT, Solomon A. Characterization of systemic amyloid deposits by mass spectrometry. Meth Enzymol 2006;412:48-62. (Pubitemid 44548573)
20. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957-4959.
21. Klein CJ, Vrana JA, Theis JD, Dyck PJ, Dyck PJ, Spinner RJ, Mauermann ML, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011;68:195-199.
22. Rowczenio D, Dogan A, Theis JD, Vrana JA, Lachmann HJ, Wechalekar AD, Gilbertson JA, et al. Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein a-I. Am J Pathol 2011;179:1978-1987.
23. Sethi S, Theis JD, Shiller SM, Nast CC, Harrison D, Rennke HG, Vrana JA, Dogan A. Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int 2011. DOI: 10.1038/ki.2011.316.
24. Sethi S, Theis JD, Leung N, Dispenzieri A, Nasr SH, Fidler ME, Cornell LD, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010;5:2180-2187.
25. Holanda DG, Acharya VK, Dogan A, Racusen LC, Atta MG. Atypical presentation of atypical amyloid. Nephrol Dial Transplant 2011;26:373-376.
26. Murphy CL, Wang S, Kestler D, Larsen C, Benson D, Weiss DT, Solomon A. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis 2010;56:1100-1107.
27. Dogan A, Vrana JA, Theis JD, Gamez JD, Kurtin PJ, Grogg KL. Mass spectrometry-based proteomic analysis of iatrogenic insulin-mediated amyloidosis (AIns). Amyloid 2010;17(Suppl 1):114.
28. Lacy MQ, Theis JD, Vrana JA, Madan S, Frederick L, Viswanathan DS, Gertz MA, Dogan A. Lysozyme amyloidosis (ALys) affecting a family with a new variant of lysozyme gene (LYX) and hereditary haemorrhagic telangiectasia. Amyloid 2010;17(Suppl 1):125.
29. Saha A, Theis JD, Vrana JA, Dubey NK, Batra VV, Sethi S. AA amyloidosis associated with hepatitis B. Nephrol Dial Transplant 2011;26:2407-2412.
30. Jullig M, Browett P, Middleditch MM, Prijic G, Kilfoyle D, Angelo N, Cooper GJ. A unique case of neural amyloidoma diagnosed by mass spectrometry of formalin-fixed tissue using a novel preparative technique. Amyloid 2011;18:147-155.
31. Davern S, Murphy CL, O'Neill H, Wall JS, Weiss DT, Solomon A. Effect of lysine modification on the stability and cellular binding of human amyloidogenic light chains. Biochim Biophys Acta 2011;1812:32-40.
32. Lavatelli F, Brambilla F, Valentini V, Rognoni P, Casarini S, Di Silvestre D, Perfetti V, et al. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. Biochim Biophys Acta 2011;1814:409-419.
33. Vrana JA, Zeldenrust SR, Theis JD, Gamez JD, Kurtin PJ, Dogan A. Diagnosis and classification of amyloidosis in abdominal subcutaneous fat aspiration specimens using mass spectrometry based proteomics. Blood 2008;112:937.
34. Vrana JA, Theis JD, Gamez JD, Kurtin PJ, Grogg KL, Dispenzieri A, Zeldenrust SR, Dogan A. Diagnosis and classification of systemic amyloidosis in abdominal subcutaneous fat aspiration specimens using mass spectrometry-based proteomics. Amyloid 2010;17(Suppl 1):55.
35. Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Rossi R, Palladini G, Obici L, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2011. PMID is 21917755.
36. Mauri P, Deho G. A proteomic approach to the analysis of RNA degradosome composition in Escherichia coli. Meth Enzymol 2008;447:99-117.
37. Stoppini M, Obici L, Lavatelli F, Giorgetti S, Marchese L, Moratti R, Bellotti V, Merlini G. Proteomics in protein misfolding diseases. Clin Chem Lab Med 2009;47:627-635.
38. Lavatelli F, Perlman DH, Spencer B, Prokaeva T, McComb ME, Theberge R, Connors LH, et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 2008;7:1570-1583.
39. Valentini V, Lavatelli F, Obici L, Donadei S, Perlini S, Palladini G, Merlini G. Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations. Amyloid 2001;18 Suppl 1:56-58.
40. Groseclose MR, Andersson M, Hardesty WM, Caprioli RM. Identification of proteins directly from tissue: in situ tryptic digestions coupled with imaging mass spectrometry. J Mass Spectrom 2007;42:254-262.
41. Aerni HR, Cornett DS, Caprioli RM. Automated acoustic matrix deposition for MALDI sample preparation. Anal Chem 2006;78:827-834. (Pubitemid 43228590)
42. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001;7:493-496. (Pubitemid 32298555)
43. Yates JR 3rd, Eng JK, McCormack AL, Schieltz D. Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. Anal Chem 1995;67:1426-1436.
44. Craig R, Beavis RC. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 2004;20:1466-1467. (Pubitemid 38931421)
45. Bodi K, Prokaeva T, Spencer B, Eberhard M, Connors LH, Seldin DC. AL-Base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences. Amyloid 2009;16:1-8.
46. Heegaard NH, Hansen MZ, Sen JW, Christiansen M, Westermark P. Immunoaffinity chromatographic and immunoprecipitation methods combined with mass spectrometry for characterization of circulating transthyretin. J Sep Sci 2006;29:371-377. (Pubitemid 43336846)
47. Bergen HR 3rd, Zeldenrust SR, Butz ML, Snow DS, Dyck PJ, Dyck PJ, Klein CJ, et al. Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem 2004;50:1544-1552. (Pubitemid 39121222)
48. Nepomuceno AI, Mason CJ, Muddiman DC, Bergen HR 3rd, Zeldenrust SR. Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization fouriertransform ion-cyclotron-resonance mass spectrometry. Clin Chem 2004;50:1535-1543. (Pubitemid 39121221)
49. Bergen HR 3rd, Zeldenrust SR, Naylor S. An on-line assay for clinical detection of amyloidogenic transthyretin variants directly from serum. Amyloid 2003;10:190-197. (Pubitemid 37372402)
50. Lim A, Prokaeva T, McComb ME, Connors LH, Skinner M, Costello CE. Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis. Protein Sci 2003;12:1775-1785. (Pubitemid 36910056)
51. Bergquist J, Andersen O, Westman A. Rapid method to characterize mutations in transthyretin in cerebrospinal fluid from familial amyloidotic polyneuropathy patients by use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2000;46:1293-1300.
52. Theberge R, Connors LH, Skinner M, Costello CE. Detection of transthyretin variants using immunoprecipitation and matrix-assisted laser desorption/ionization bioreactive probes: a clinical application of mass spectrometry. J Am Soc Mass Spectrom 2000;11:172-175. (Pubitemid 34506435)
53. Theberge R, Connors L, Skinner M, Skare J, Costello CE. Characterization of transthyretin mutants from serum using immunoprecipitation, HPLC/electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry. Anal Chem 1999;6:54-58.
54. Theberge R, Infusini G, Tong W, McComb ME, Costello CE. Top-Down Analysis of Small Plasma Proteins Using an LTQ-Orbitrap. Potential for Mass Spectrometry-Based Clinical Assays for Transthyretin and Hemoglobin. Int J Mass Spectrom 2011;300:130-142.
55. Bergen HR 3rd, Abraham RS, Johnson KL, Bradwell AR, Naylor S. Characterization of amyloidogenic immunoglobulin light chains directly from serum by on-line immunoaffinity isolation. Biomed Chromatogr 2004;18:191-201. (Pubitemid 38584838)